Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) EBIT Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBIT Margin for 7 consecutive years, with 306.24% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 63896.0% to 306.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.02% through Dec 2025, up 64223.0% year-over-year, with the annual reading at 12.02% for FY2025, 64223.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 306.24% at Beam Therapeutics, up from 1307.6% in the prior quarter.
  • The five-year high for EBIT Margin was 306.24% in Q4 2025, with the low at 3339550.0% in Q1 2021.
  • Average EBIT Margin over 5 years is 217150.8%, with a median of 688.06% recorded in 2024.
  • The sharpest move saw EBIT Margin crashed -286696667bps in 2021, then soared 333864600bps in 2022.
  • Over 5 years, EBIT Margin stood at 124.31% in 2021, then crashed by -257bps to 444.1% in 2022, then soared by 109bps to 42.02% in 2023, then crashed by -892bps to 332.71% in 2024, then soared by 192bps to 306.24% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 306.24%, 1307.6%, and 1419.22% for Q4 2025, Q3 2025, and Q2 2025 respectively.